Aniara Diagnostica would like to announce the availability of Biophen Anti-Xa and Biophen Anti-IIa, two-stage Chromogenic Assays

Aniara Diagnostica distributes Biophen Anti-Xa and Biophen Anti-IIa, two-stage chromogenic assays which follow USP and EP standards for the Heparin Anti-Xa and Anti-IIa activity.

WEST CHESTER, Ohio, Jan. 16, 2020 /PRNewswire-PRWeb/ -- Aniara Diagnostica, a multi-national distributor of diagnostic and research agents, as well as screening tools, has strengthened its commitment to meeting today's highest Industrial QC Heparin standards.

These products are for Research Use Only and not for use in Diagnostic procedures.

Specific kits are USP/EP compliant

USP/EP Compliant Heparin QC Kits Chromogenic Anti-IIa and Anti-Xa methods are used for measuring homogeneous Heparin for Quality Control (QC testing). These kits are two stage chromogenic assay used for measuring the activity of heparins (UFH or LMWH) in a manual or automated method.

BIOPHEN Heparin Anti-IIa (2 stages) A220005 Click here for more information

BIOPHEN Heparin Anti-Xa (2 stages) A221005Click here for more information

Follow the link to read more on USP Potency Adjusted Bovine Mucosal Heparins (BMH) Are Comparable to Porcine Mucosal Heparins (PMH) at Equivalent Levels

The entire Aniara product line is available for purchase at http://www.aniara.com. The Company distributes products in North America, Central America, South America, Sweden, Norway, Denmark, Finland, Lithuania, Latvia, Estonia and Iceland.

SOURCE Aniara Diagnostica

Latest Press Release on Drug News

UT Health San Antonio to lead $11 million, NIH-funded study of a first-ever oral chlamydia vaccine

The University of Texas Health Science Center at San Antonio (UT Health San Antonio) will direct a team of researchers to investigate a novel oral vaccine for chlamydia, the most rep...

GIBF invests $10 Million in Nectin Therapeutics to Advance Novel Pipeline of First-in-Class Immunotherapies and Antibody Drug Conjugates

Proceeds from financing to support ongoing clinical development of lead program targeting PVR as well as IND-enabling activities for multiple ADC candidates TEL AVIV, Israel , ...

Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons

A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seasons in the United States . The study suggests th...

Foresee Pharmaceuticals Announces First Subject Dosed in its First-in-Human Clinical Trial of FP-020

TAIPEI , April 30, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that the first subject has been dosed in its Phase 1 clinical trial of FP...

PANTHERx® Rare Partnering with X4 Pharmaceuticals Inc. for the Distribution of XOLREMDI™ (mavorixafor), the First FDA-Approved Therapy Indicated for Use in Patients with WHIM Syndrome

PITTSBURGH , April 29, 2024 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, today announced it was selec...